Terns Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, will present preclinical data on their novel allosteric BCR-ABL inhibitor, TERN-701, at the 30th European Hematology Association Congress (EHA25) in Milan, Italy. The event will take place from June 12-15, 2025. The presentation, scheduled for June 13, 2025, will highlight the potency of TERN-701 against various resistance mutations in chronic myeloid leukemia $(CML.UK)$, showcasing its potential clinical benefits over existing therapies.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。